Patent · US Active

Therapeutic antibodies binding IL12Rβ1

US8715657B2 · kind B2 · utility

1Cited by

2References

15Claims

0Family size

Assignee

Novartis AG · CH

Inventors

Michael Bardroff · Soest, DE
Jose M. Carballido Herrera · Allschwil, CH
Daniela Della Ducata · Munich, DE
Christoph Heusser · Oberwil, CH
Ute Jaeger · Munich, DE
Christoph Schwaerzler · La Valette-du-Var, FR

Key dates

Filing date	Mar 29, 2010
Grant date	May 6, 2014
Priority date	—
Expiry date	Mar 30, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/32
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of the heterodimeric IL12 receptor (together with IL12Rβ2 chain) as well as IL23 receptor (together with IL23Rα chain). The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFNγ production of T cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNγ production, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.